
Fast action saves lives
When experiencing a stroke, fast action plays a major role in recovery potential.
COVID-19: Everything you need to know about patient and visitor information.
The Alfred Neuroscience Clinical Trials Unit is the largest clinical trial site of its kind in Australia. We are the only clinical trials unit with a dedicated inpatient early phase neuroscience clinical trials unit.
We need clinical trials to prove that a new medication, device or treatment is safe and effective for people.
Without clinical trials, new treatments and medicines cannot be approved for use in Australia.
With more than 50 clinical trials open at any one time, we are fast becoming a world leader in trialling new treatments for brain conditions that have historically been untreatable.
Our highly developed and innovative clinical trial program has the capacity to manage the entire medication discovery pipeline at one site:
We have a dedicated four bed inpatient early phase neuroscience clinical trials unit with capacity for:
Our neuroscience clinical trials are highly sought-after by pharmacological and biotech companies for world-first national and international neurological clinical trials. We attract grants and sponsors because we have unique, word-class facilities combined with internally recognised specialists in neurological diseases. We also have well-characterised patient cohorts.
The Alfred Brain team continues its groundbreaking work in the functional neurosurgery space.
Alison checks Olivia's Vagus Nerve Stimulator (VNS) in the Epilepsy Clinic.
Some important visitors meet one of our neurology patients.
There are four different phases of a clinical trial. Each phase is represented by a roman numeral.
We conduct clinical trials for new medications and devices for nervous disorders such as:
The Alfred Neuroscience Clinical Trials team are leaders in their fields, with decades of Australian and international experience.
Prof O'Brien is the Program Director Alfred Brain, Deputy Director of Research and Head of Neuroscience Clinical Trials Unit at The Alfred.
Prof Patrick Kwan is the Director of Epilepsy: Genomics, Personalised Medicine at Alfred Health.
Dr Elspeth Hutton is the Deputy Director of Neurology and Head of Headache, Neuromuscular and Pain at Alfred Health.
A/Prof Anneke Van Der Walt is the Director of Multiple Sclerosis and Neuroimmunology at Alfred Health.
Dr Mastura Monif is the Head of Neuroimmunology and Neuroinflammation at Alfred Health.
Prof Geoffrey Cloud is the Director of Stroke at Alfred Health.
Dr Kelly Bertram is the Head of Movement Disorders at Alfred Health.
A/Prof Martin Hunn is the Director of Neurosurgery at Alfred Health.
A/Prof David Darby in the Lead for Dementia Trials at Alfred Health.
Prof Helmut Butzkueven is the Director of Neurology and MS Trials at Alfred Health.
ClinTrial Refer is a quick way to see all of our open trials, in one place. It’s the easy way to find a trial that may be right for you or your patient.
When experiencing a stroke, fast action plays a major role in recovery potential.
Matt was diagnosed with an aggressive brain tumour called a glioblastoma - he's recently completed six weeks of radiation therapy. For patients like Matt, after having brain surgery the next step in brain cancer treatment is radiation therapy and chemotherapy.
Treating brain cancer is a team effort, when a person is suspected of having a brain tumour they’ll begin their journey through treatment, starting with the first stop - Neuroradiology.